FDA WARNING_LETTER - directmeds.com, Inc. dba DirectMeds - August 01, 2025

On September 9, 2025, the FDA issued a warning letter to directmeds.com, Inc., doing business as DirectMeds, following a review of the company"s website in August 2025. The investigation revealed that the company was marketing compounded drug products, specifically semaglutide and tirzepatide, using false and misleading claims. The website suggested that these compounded versions were identical to FDA-approved brand-name drugs because they contained the "same active ingredient." However, the FDA noted that compounded drugs are not FDA-approved, and implying equivalence to approved medications is deceptive to consumers. These actions violate the Federal Food, Drug, and Cosmetic Act (FDCA), which classifies such products as misbranded when their advertising or labeling is misleading. The FDA stated that introducing these misbranded drugs into interstate commerce is a prohibited act. DirectMeds is required to take immediate action to correct these violations, including removing the misleading promotional language. The company must submit a written response within 15 working days detailing the specific steps taken to address the issues and prevent their recurrence. Failure to comply with these requirements may lead to legal consequences, such as product seizures or court-ordered injunctions.